uniQure N.V. (NASDAQ: QURE) and BIOVERATIV INC (NASDAQ:BIVV) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, analyst recommendations, profitabiliy, earnings and risk.
This is a breakdown of current ratings for uniQure N.V. and BIOVERATIV INC, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
uniQure N.V. presently has a consensus price target of $16.57, indicating a potential upside of 230.77%. BIOVERATIV INC has a consensus price target of $54.55, indicating a potential downside of 9.89%. Given uniQure N.V.’s stronger consensus rating and higher possible upside, equities research analysts clearly believe uniQure N.V. is more favorable than BIOVERATIV INC.
This table compares uniQure N.V. and BIOVERATIV INC’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares uniQure N.V. and BIOVERATIV INC’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|uniQure N.V.||$24.12 million||5.28||-$66.07 million||($2.64)||-1.90|
|BIOVERATIV INC||$954.80 million||6.86||$398.80 million||N/A||N/A|
BIOVERATIV INC has higher revenue and earnings than uniQure N.V..
Insider and Institutional Ownership
30.5% of uniQure N.V. shares are held by institutional investors. Comparatively, 90.6% of BIOVERATIV INC shares are held by institutional investors. 0.6% of uniQure N.V. shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
BIOVERATIV INC beats uniQure N.V. on 8 of the 12 factors compared between the two stocks.
About uniQure N.V.
uniQure N.V. (uniQure) is a gene therapy company. The Company is engaged in developing single treatments with curative results for patients suffering from genetic and other severe diseases. The Company is advancing a focused pipeline of gene therapies that have been developed both internally and through partnerships. The Company’s product candidates include AMT-060 for Hemophilia B, AMT-130 for Huntington’s disease, S100A1 for congestive heart failure and Glybera for lipoprotein lipase deficiency (LPLD). uniQure has established clinical proof-of-concept in its lead indication, hemophilia B and has achieved pre-clinical, proof-of-concept in Huntington’s disease. The Company, through its collaboration with Bristol Myers-Squibb (BMS), is focused on building a portfolio of gene therapies led by the S100A1 program for congestive heart failure.
About BIOVERATIV INC
Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person’s blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.